New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
Inclacumab was generally well tolerated in THRIVE-131
Subscribe To Our Newsletter & Stay Updated
